Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

Sponsor
NHS Greater Glasgow and Clyde
Study ID
NCT07443956
Status
Recruiting
Apply to this trial

Conditions

  • Obesity & Overweight
  • Psoriatic Arthritis (PsA)

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a trial to find out how weight loss (achieved by the use of tirzepatide) or ixekizumab treatment affects the characteristics of skin, joint and fat tissues in patients with Psoriatic Arthritis, Psoriasis and obesity/overweight BMI \>=27. Participants will be allocated either Tirzepatide, Ixekizumab or both. Samples of joint tissue, fat and skin will be taken at the start of the study and week 12. Blood and urine samples will also be taken. The primary objective will be to assess the changes seen in the joint, fat and skin tissue samples 12 weeks after starting the medications (additional analysis will be done on the optional 36 week samples). Secondary objectives will be * To assess the changes seen in blood 4, 12, 36 and 52 weeks after starting the medication. * To compare the changes seen in tissue and blood between Ixekizumab and Tirzepatide/Weight loss. * To see how the changes seen in the tissue relate to weight loss.

Key Dates

Start date
Mar 9, 2026
Status verified
Apr 2026
Primary completion
Feb 29, 2028
Completion
May 31, 2030

Study Design

Enrollment
45 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: Tirzepatide group
  • Active Comparator: Ixekizumab group
  • Active Comparator: Combined tirzepatide and ixekizumab

Primary Outcome Measure

Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss [ Time Frame: 12 weeks ]

Central Contacts

Related Studies